Market revenue in 2022 | USD 220.4 million |
Market revenue in 2030 | USD 1,431.1 million |
Growth rate | 26.3% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 63.61% in 2022. Horizon Databook has segmented the Spain cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Spain is gaining reputation in cell and gene therapy research due to expansion of major players within the country. For instance, in July 2021, Pfizer announced that they will be setting up a biotechnology plant focusing on distribution of genetic therapies across Europe.
This initiative was taken was specifically to advance treatment options for rare genetic diseases. With growing demand for advanced therapy products in the country, several companies and clinics are entering the Spanish market.
For instance, in October 2019, VIRALGEN opened a new manufacturing plant fore gene therapy in the country. This plant is expected to be one of the most modern in Europe. VIRALGEN is a leading manufacturing partner in Spain, and in September 2020, the company signed a production agreement with CombiGene AB for manufacturing of CG01—a gene therapy product for the treatment of drug-resistant focal epilepsy.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Spain cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account